Trial Profile
A Phase 2 Controlled Trial of a Single ProHema-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs FT 1050 (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Acronyms PUMA
- Sponsors Fate Therapeutics
- 11 Apr 2016 Status changed from recruiting to discontinued. Reason the study was stopped: Business decision
- 21 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 21 Sep 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.